Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Terminated 3

Sponsor Class

NIH 40OTHER 4INDUSTRY 4NETWORK 3

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × alvocidib × Clear all
NCT03298984 2023-11-15

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Sumitomo Pharma America, Inc.

Phase 1 Completed
32 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03563560 2022-04-12

AML

Sumitomo Pharma Co., Ltd.

Phase 1 Completed
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03441555 2022-02-01

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AbbVie

Phase 1 Completed
36 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT00464633 2013-02-12

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Sanofi

Phase 2 Completed
165 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡